- Home
- TRUG vs JAGX Comparison
TRUG vs JAGX Comparison
Compare TRUG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- JAGX
- Stock Information
- Founded
- TRUG 1983
- JAGX 2013
- Country
- TRUG United States
- JAGX United States
- Employees
- TRUG N/A
- JAGX N/A
- Industry
- TRUG
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- JAGX Health Care
- Exchange
- TRUG NYSE
- JAGX Nasdaq
- Market Cap
- TRUG 8.4M
- JAGX 7.4M
- IPO Year
- TRUG N/A
- JAGX N/A
- Fundamental
- Price
- TRUG $0.23
- JAGX $4.06
- Analyst Decision
- TRUG Strong Buy
- JAGX Strong Buy
- Analyst Count
- TRUG 1
- JAGX 1
- Target Price
- TRUG $2.00
- JAGX $60.00
- AVG Volume (30 Days)
- TRUG 9.9M
- JAGX 108.3K
- Earning Date
- TRUG 05-15-2025
- JAGX 05-15-2025
- Dividend Yield
- TRUG N/A
- JAGX N/A
- EPS Growth
- TRUG N/A
- JAGX N/A
- EPS
- TRUG N/A
- JAGX N/A
- Revenue
- TRUG $22,236,072.00
- JAGX $11,552,000.00
- Revenue This Year
- TRUG $24.05
- JAGX $22.41
- Revenue Next Year
- TRUG $31.65
- JAGX $30.00
- P/E Ratio
- TRUG N/A
- JAGX N/A
- Revenue Growth
- TRUG 8.40
- JAGX 13.93
- 52 Week Low
- TRUG $0.17
- JAGX $3.75
- 52 Week High
- TRUG $1.52
- JAGX $110.75
- Technical
- Relative Strength Index (RSI)
- TRUG 44.78
- JAGX 33.50
- Support Level
- TRUG $0.21
- JAGX $4.27
- Resistance Level
- TRUG $0.25
- JAGX $4.90
- Average True Range (ATR)
- TRUG 0.05
- JAGX 0.49
- MACD
- TRUG 0.00
- JAGX -0.04
- Stochastic Oscillator
- TRUG 21.98
- JAGX 9.27
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.